• LAST PRICE
    0.5301
  • TODAY'S CHANGE (%)
    Trending Down-0.0625 (-10.5467%)
  • Bid / Lots
    0.5100/ 10
  • Ask / Lots
    0.6801/ 5
  • Open / Previous Close
    0.5748 / 0.5926
  • Day Range
    Low 0.4631
    High 0.6400
  • 52 Week Range
    Low 0.4631
    High 10.5300
  • Volume
    134,452
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.5926
TimeVolumeAYLA
09:32 ET20120.6222
09:46 ET3030.5801
09:50 ET1000.5801
09:51 ET25000.596457
11:05 ET286810.4677
11:12 ET1000.5389
11:14 ET1000.53895
11:16 ET1000.539
11:27 ET20000.5599
11:36 ET1000.52
11:38 ET5000.5102
11:41 ET10000.5299
11:52 ET6500.5299
11:54 ET3000.5238
11:59 ET23000.519
12:03 ET12000.5191
12:10 ET1000.5191
12:21 ET4000.5196
12:26 ET13800.519
12:28 ET1000.5191
12:30 ET2000.5285
12:33 ET4750.5399
12:37 ET10000.5302
12:55 ET3000.535
01:38 ET2600.54
01:42 ET13800.54
01:44 ET3670.57999
01:51 ET95390.58
01:56 ET100000.5902
01:58 ET5000.5901
02:00 ET99180.5901
02:07 ET1000.590101
02:09 ET50000.5901
02:12 ET50000.5901
02:23 ET102000.64
02:27 ET100000.59
02:36 ET108210.59
02:41 ET80000.589999
03:48 ET2000.54
03:55 ET1000.5599
03:57 ET34130.5302
04:00 ET14520.5301
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAYLA
Ayala Pharmaceuticals Inc
8.8M
-0.2x
---
United StatesENSC
Ensysce Biosciences Inc
8.3M
-0.1x
---
United StatesAGRX
Agile Therapeutics Inc
8.1M
0.0x
---
United StatesOPGN
OpGen Inc
9.1M
-0.2x
---
United StatesACUR
Acura Pharmaceuticals Inc
3.3M
-1.8x
---
United StatesTCBP
TC BioPharm Ltd
3.7M
-0.2x
---
As of 2022-11-29

Company Information

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The Company's portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors (GSIs). AL101 and AL102 are designed to address the underlying key drivers of tumor growth. The Company is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC), for patients bearing Notch-activating mutations. The Company also developing AL102 for the treatment of other rare indications including T-ALL, an aggressive, rare form of T-cell specific leukemia. The Company is also conducting its ongoing Phase II ACCURACY trial for the treatment of R/M ACC in subjects with progressive disease and Notch-activating mutations.

Contact Information

Headquarters
1313 N. Market Street, Suite 5100WILMINGTON, DE, United States 19801
Phone
857-444-0553
Fax
---

Executives

Independent Chairman of the Board
David Sidransky
Chief Executive Officer
Kenneth Berlin
Chief Financial Officer
Igor Gitelman
Chief Medical Officer
Gary Gordon
Independent Director
Vered Bisker-Leib

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$8.8M
Revenue (TTM)
$1.7M
Shares Outstanding
14.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.51
Book Value
$2.45
P/E Ratio
-0.2x
Price/Sales (TTM)
5.1
Price/Cash Flow (TTM)
---
Operating Margin
-2,166.30%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.